Spots Global Cancer Trial Database for tyrosine kinase inhibitor
Every month we try and update this database with for tyrosine kinase inhibitor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey | NCT03647215 | Chronic Phase C... Accelerated Pha... Blastic Phase C... Philadelphia Ch... | 18 Years - | Incyte Corporation | ||
| Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) | NCT02260505 | Gastrointestina... Resected Gastro... Non-metastatic High Risk of Re... KIT Gene Mutati... | Imatinib mainte... | 18 Years - | Centre Leon Berard | |
| Cabozantinib for Advanced Urothelial Cancer | NCT01688999 | Urothelial Carc... Urethral Neopla... Urinary Bladder... Kidney Neoplasm... | Cabozantinib | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer | NCT00389441 | Thyroid Neoplas... | AG-013736 | 18 Years - | Pfizer | |
| Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma | NCT03035630 | Clear-cell Rena... RCC Kidney Cancer Clear-cell Kidn... | Avelumab Sunitinib | 18 Years - | Hoosier Cancer Research Network | |
| Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia | NCT00852566 | Chronic Myeloid... | Imatinib Dasatinib | 18 Years - | Norwegian University of Science and Technology | |
| Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer | NCT02219711 | Advanced Cancer | MGCD516 | 18 Years - | Mirati Therapeutics Inc. | |
| Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations | NCT03799094 | Carcinoma, Non-... | Vitamin C Tyrosine kinase... | 18 Years - 75 Years | Clifford Hospital, Guangzhou, China | |
| Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer | NCT05748834 | Breast Cancer | Tucatinib Doxil | 18 Years - | SCRI Development Innovations, LLC | |
| Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia | NCT04006847 | Chronic Myeloid... | Eicosapentaenoi... Tyrosine kinase... | 18 Years - | Milton S. Hershey Medical Center | |
| Phase 2 Study of Dacomitinib in NSCLC | NCT04027647 | NSCLC Stage III... NSCLC Stage III... NSCLC Stage IV Recurrent NSCLC EGFR Positive N... | Dacomitinib | 18 Years - | National Cancer Centre, Singapore | |
| Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations | NCT02949843 | EGFR Activating... Recurrent Non-S... Stage IV Non-Sm... | Chemotherapy Immunotherapy Laboratory Biom... Nivolumab Pembrolizumab Targeted Molecu... Tyrosine Kinase... | - | Wake Forest University Health Sciences | |
| Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs | NCT03106779 | Chronic Myeloge... | Asciminib Bosutinib | 18 Years - | Novartis | |
| A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments | NCT05152472 | Unresectable Ga... Locally Advance... Metastatic Gast... | Atezolizumab 12... Imatinib 400 MG | 18 Years - | Centre Leon Berard | |
| Targeted Therapy Selection Based on Tumor Tissue Kinase Activity Profiles for Patients With Advanced Solid Malignancies, an Exploratory Study | NCT01190241 | Advanced Solid ... Inoperable Metastasis | desatinib or su... | 18 Years - | Amsterdam UMC, location VUmc | |
| Erlotinib Concurrent With Radiation Therapy in Non-small-cell Lung Cancer | NCT00973310 | Carcinoma, Non-... | Radiation Thera... | 18 Years - 70 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001) | NCT01833572 | Non-small-cell ... | Gefitinib | 18 Years - | Fudan University | |
| Liver Function Test (LFT) Elevations in Cancer Patients and Users of Tyrosine Kinase Inhibitor (TKI) Drugs | NCT01098500 | Cancer | Tyrosine kinase... | 18 Years - | GlaxoSmithKline | |
| A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Positive | NCT05603156 | Ph+ ALL Bone Marrow Tra... Minimal Residua... | the usage of Ol... | 18 Years - | Institute of Hematology & Blood Diseases Hospital, China | |
| A Study of Dasatinib Plus Reduced Intensive Consolidation Chemotherapy in Ph+ Adult ALL | NCT05026229 | Precursor Cell ... Philadelphia-Po... ALL, Adult | dasatinib plus ... dasatinib plus ... | 18 Years - 65 Years | First Affiliated Hospital Xi'an Jiaotong University | |
| Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer | NCT00861471 | Prostate Cancer Prostatic Neopl... | Docetaxel Imatinib Mesyla... | 18 Years - | NYU Langone Health | |
| Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) | NCT03964090 | Central Nervous... Secondary Centr... | TEDD-R TEDDI-R Ibrutinib Cytarabine Isavuconazole Methotrexate | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer | NCT00389441 | Thyroid Neoplas... | AG-013736 | 18 Years - | Pfizer | |
| Prospective Study on Resistance-associated Mutations in Metastatic Lung Cancer | NCT06081270 | Lung Cancer | Liquid biopsy | 18 Years - | University of Milano Bicocca | |
| Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants | NCT03624530 | Philadelphia Ch... Tyrosine Kinase... Minimal Residua... Allogeneic Hema... | Tyrosine kinase... | 14 Years - 65 Years | Nanfang Hospital, Southern Medical University | |
| Biomarkers of Angiogenesis for Response to Therapeutic Combination in Advanced or Metastatic Kidney Cancer | NCT05285579 | Renal Cell Carc... Renal Cancer Renal Cancer Me... | Blood collectio... Tumour samples | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL | NCT03564470 | Leukemia Leukemia, Acute Leukemia, Lymph... Leukemia, B-cel... | Chidamide Dasatinib | 14 Years - 55 Years | Nanfang Hospital, Southern Medical University | |
| Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST) | NCT00116935 | Sarcoma | imatinib mesyla... imatinib imatinib | 18 Years - | Scandinavian Sarcoma Group | |
| Predicting Response to Systemic Therapies for Hepatocellular Carcinoma(HCC) | NCT05543304 | Hepatocellular ... Effect of Drug | radiological ev... | 18 Years - 80 Years | First Affiliated Hospital of Wenzhou Medical University | |
| Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia | NCT00782067 | Leukemia | Midostaurin (PK... | 18 Years - | Novartis | |
| Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients | NCT00493181 | Leukemia Chronic Myeloge... Chronic Myeloid... | Interleukin-11 ... | - | M.D. Anderson Cancer Center | |
| Bevacizumab Combined With Double Dose Icotinib in Patients With EGFR Exon 21-L858R Mutation | NCT05263947 | Carcinoma, Non-... Bevacizumab EGF-R Positive ... Tyrosine Kinase... | Bevacizumab and... | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias | NCT00261846 | Chronic Myeloid... | Bosutinib | 18 Years - | Pfizer | |
| Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for Newly Diagnosed Glioblastoma | NCT04157478 | Glioblastoma | Anlotinib Hydro... Radiation thera... Temozolomide | 18 Years - 75 Years | People's Hospital of Guangxi | |
| Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST) | NCT01323400 | GIST | Pazopanib Best supportive... | 18 Years - 90 Years | Centre Leon Berard | |
| Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage | NCT04440267 | Acute Leukemia ... | vincristine daunorubicin cyclophosphamid... L-Asparaginase prednisone mercaptopurine methotrexate dexamethasone Tyrosine kinase... | 14 Years - | Institute of Hematology & Blood Diseases Hospital, China | |
| A Combination of Pazopanib and Carboplatin in Advanced Solid Malignancies | NCT01542047 | Cancer, Metasta... | Carboplatin Pazopanib | 18 Years - | New Mexico Cancer Care Alliance | |
| Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma | NCT03680521 | Clear Cell Rena... | Sitravatinib Nivolumab | 18 Years - | Mirati Therapeutics Inc. | |
| Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas | NCT04055220 | Bone Sarcoma Osteosarcoma Ewing Sarcoma Chondrosarcoma Undifferentiate... Leiomyosarcoma Angiosarcoma | Treatment by Re... Treatment by Pl... | 12 Years - | Centre Leon Berard | |
| A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma | NCT01865747 | Renal Cell Carc... | Cabozantinib ta... Everolimus (Afi... | 18 Years - | Exelixis | |
| Expanded Access Program of Ponatinib | NCT01592136 | Chronic Myeloid... Philadelphia Ch... | ponatinib | 18 Years - | Takeda | |
| Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping | NCT04318938 | NSCLC | Brigatinib Tyrosine kinase... | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| Predicting Response to Systemic Therapies for Hepatocellular Carcinoma(HCC) | NCT05543304 | Hepatocellular ... Effect of Drug | radiological ev... | 18 Years - 80 Years | First Affiliated Hospital of Wenzhou Medical University | |
| Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma | NCT00942877 | Sarcoma, Alveol... | AZD2171 | - 16 Years | National Institutes of Health Clinical Center (CC) | |
| Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Advanced Non Small Cell Lung Cancer | NCT02274337 | Non-Small Cell ... | AC0010 | 18 Years - 70 Years | Sun Yat-sen University | |
| Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia | NCT03817398 | Chronic Phase C... | Biospecimen Col... Drug Withdrawn Quality-of-Life... Questionnaire A... Tyrosine Kinase... | - 25 Years | Children's Oncology Group | |
| Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer. | NCT02335944 | Non Small Cell ... | Capmatinib Nazartinib | 18 Years - | Novartis | |
| Fingerprint Characterization Tyrosine Kinase Inhibitors in Advanced HCC | NCT03958669 | Hepatocellular ... Sorafenib | 18 Years - | University Hospital Tuebingen | ||
| Oncotool for Cancer Medications | NCT03952312 | Cancer Cancer, Treatme... Medication Adhe... Communication Tyrosine Kinase... | Oncotool Interv... Oncotool Contro... | 18 Years - | Northwestern University | |
| Metabolic Alternation and Clinicohematological Characteristic in Chronic Phase CML in Patient Treated With TKI | NCT06121765 | CML, Chronic Ph... | Tyrosine kinase... | 18 Years - 75 Years | Assiut University | |
| HRQOL in Locally Advanced Thyroid Carcinoma | NCT05824312 | Thyroid Cancer Tyrosine Kinase... Health Related ... | Tyrosine kinase... | 18 Years - 70 Years | Fujian Cancer Hospital | |
| Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation | NCT01243489 | Chronic Myeloge... | compliance supp... | 18 Years - | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | |
| Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) | NCT03578367 | CML Chronic Myeloge... Leukemia, Myelo... Hematologic Dis... | Asciminib add-o... Imatinib Nilotinib Asciminib singl... | 18 Years - | Novartis | |
| Cetuximab as Therapy for Recurrent Non-Small Cell Lung Cancer Patients Who Have Received Prior Therapy | NCT00694603 | Non-small Cell ... | Cetuximab | 18 Years - | Massachusetts General Hospital | |
| Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma | NCT02203526 | Primary Central... | Isavuconazole TEDDI Rituximab Cytarabine TEDD Ibrutinib (Arms... Methotrexate Ibrutinib (Arm ... Ibrutinib (Arm ... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors | NCT05949632 | Advanced Solid ... | INCB099280 axitinib | 18 Years - | Incyte Corporation | |
| Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias | NCT00261846 | Chronic Myeloid... | Bosutinib | 18 Years - | Pfizer | |
| HRQOL in Locally Advanced Thyroid Carcinoma | NCT05824312 | Thyroid Cancer Tyrosine Kinase... Health Related ... | Tyrosine kinase... | 18 Years - 70 Years | Fujian Cancer Hospital | |
| An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer | NCT02365597 | Urothelial Canc... | Erdafitinib Midazolam Metformin | 18 Years - | Janssen Research & Development, LLC | |
| Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation | NCT01405079 | Non-small Cell ... | Gefitinib Vinorelbine+Cis... | 18 Years - 75 Years | Guangdong Association of Clinical Trials | |
| Real-world Analysis of Workup at Disease Progression and Implementation of Osimertinib for EGFR+ NSCLC | NCT04105153 | EGFR Positive N... | 18 Years - | Thoraxklinik-Heidelberg gGmbH | ||
| Ph II CABOGIST in GIST | NCT02216578 | Metastatic Gast... | cabozantinib | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients | NCT02490488 | Ovarian Cancer | Masitinib Gemcitabine Placebo | 18 Years - | AB Science | |
| TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTT | NCT04967495 | Hepatocellular ... | TACE combined w... TACE combined w... | 18 Years - 75 Years | Second Affiliated Hospital of Guangzhou Medical University | |
| Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations | NCT03799094 | Carcinoma, Non-... | Vitamin C Tyrosine kinase... | 18 Years - 75 Years | Clifford Hospital, Guangzhou, China | |
| A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma | NCT05456256 | Adenocarcinoma ... Carcinoma, Non-... | LP-300 Pemetrexed Carboplatin | 18 Years - | Lantern Pharma Inc. | |
| Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients | NCT01599754 | Clear Cell Rena... | Axitinib Placebo | 18 Years - | SFJ Pharmaceuticals, Inc. | |
| Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer | NCT03630120 | Thyroid Cancer Thyroid Cancer,... Differentiated ... Papillary Thyro... Follicular Thyr... Poorly Differen... | Lenvatinib Sorafenib Cabozantinib Vandetanib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study of Pazopanib Versus Placebo as Maintenance Therapy for Advanced Soft Tissue Sarcoma | NCT02367651 | Sarcoma, Soft T... | Pazopanib 800 m... Placebo | 18 Years - | GlaxoSmithKline | |
| Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus Treatment | NCT02646020 | Non-small Cell ... | Aprepitant Desloratadine Placebo of apre... Placebo of desl... | 18 Years - | Sun Yat-sen University | |
| Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML Patients: Observatory Trial Studying the Biological Factors. | NCT03996096 | Chronic Myeloid... Tyrosine Kinase... Withdrawal Synd... | 18 Years - | University Hospital, Caen | ||
| Imatinib in Dermatofibrosarcoma Protuberans (DFSP) | NCT00122473 | Dermatofibrosar... | Imatinib (Glive... | 18 Years - | Dermatologic Cooperative Oncology Group | |
| Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitor in Patients With Chronic Myeloid Leukemia | NCT05259228 | Tyrosine Kinase... Pharmacokinetic... Therapeutic Dru... | 20 Years - | National Taiwan University Hospital | ||
| Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia | NCT00079313 | Chronic Myelomo... Chronic Myeloge... | Imatinib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors | NCT03934372 | Acute Myeloid L... Accelerated Pha... Blast Phase Chr... Chronic Phase C... Acute Lymphobla... Acute Lymphocyt... Leukemia Lymphoma Solid Tumors | Ponatinib | 1 Year - 17 Years | Incyte Corporation | |
| Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) | NCT03578367 | CML Chronic Myeloge... Leukemia, Myelo... Hematologic Dis... | Asciminib add-o... Imatinib Nilotinib Asciminib singl... | 18 Years - | Novartis | |
| Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations | NCT02949843 | EGFR Activating... Recurrent Non-S... Stage IV Non-Sm... | Chemotherapy Immunotherapy Laboratory Biom... Nivolumab Pembrolizumab Targeted Molecu... Tyrosine Kinase... | - | Wake Forest University Health Sciences | |
| Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping | NCT04318938 | NSCLC | Brigatinib Tyrosine kinase... | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer. | NCT02335944 | Non Small Cell ... | Capmatinib Nazartinib | 18 Years - | Novartis | |
| Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia | NCT05130138 | Chronic Myeloid... | Pharmaceutical ... | 18 Years - | Centre Hospitalier Universitaire de Saint Etienne |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
